CURE Pharma Harnesses Cannabinoids to Fight Cancer
Ryan Allway
June 1st, 2017
News, Top News
Cannabis extracts have been used for decades to treat medical ailments, but research into cannabinoid-based therapeutics for cancer is relatively new due to federal prohibition. In early studies, researchers have found that cannabinoids and terpenes could have strong anti-tumor effects at certain doses, which makes them a compelling target for a U.S. market that’s expected to reach $23 billion by 2020, according to ArcView Research.
In this article, we will look at CURE Pharmaceutical’s (OTCQB: CURR) collaboration with Technion and its plans to advance cannabinoid-based therapeutics targeting cancer.
Cannabinoids and Cancer
The use of cannabis extracts for medicinal purposes is well-documented throughout history, but clinical trials have been hampered by the federal government’s stance on the drug. With state and federal rules relaxed, new research has found that tetrahydrocannabinol (THC) and cannabidiol (CBD) could have anti-tumor properties at various doses by impacting the signaling taking place within the human endocannabinoid system.
Earlier this month, CURE Pharmaceutical established a pharmaceutical cannabinoid division to research and develop clinically-ready cannabinoid drug formulations and delivery systems. The company will leverage its existing infrastructure to accelerate these efforts, including its integrated drug discovery, proprietary extraction technology, genetic-specific cannabinoid research, and innovative drug development platform.
“We are well-positioned in the pharmaceutical cannabis sector and excited to work within an industry with such a promising future,” said CURE CEO Rob Davidson. “Our goal is to bring new cannabinoid molecules to market through the FDA regulatory process, while utilizing our company’s proprietary delivery technologies to increase efficacy, as well as target unmet needs in traditional pharmaceutical markets that could be disrupted.”
The company’s CureFilm™ delivery technology is a flavorful dissolvable film that delivers active pharmaceutical ingredients (APIs) to patients in the most effective and convenient manner. CureFilm™ can be manufactured to dissolve at different intervals for faster absorption through the mouth or slower absorption through the gastrointestinal tract, while multiple APIs can be stored on a single strip – eliminating the need for multiple pills or medications.
Collaborating with a Leader
CURE Pharmaceutical recently announced a strategic partnership and collaboration with Technion Research and Development Foundation Ltd. – a wholly-owned subsidiary of the Technion-Israel Institute of Technology – to research how different cannabinoid compounds within cannabis strains can be used to treat various subtypes of cancer, including prostate cancer and leukemia, as well as predict what strains work best.
“This research partnership with Technion, which has one of the leading cannabis laboratories in the world, is a crucial step in our ultimate goal to bring new cancer fighting molecules to market,” said CURE CEO Rob Davidson. “In this work, the Technion team aims to clarify the antitumor effects of phytocannabinoids and terpenes on various cancer driving mutations and pathways, as well as further elucidating the mechanism of the cannabinoid-mediated anti-tumor effects.”
Researchers at Technion’s laboratory have established a method for screening anti-tumor effects of cannabinoid compounds on various cancer subtypes in vitro. In addition, the group recently discovered two new pathways that have been activated by cannabis extracts in cancer cells. These milestones underscore the organization’s experience in the cannabinoid research space, particularly as it applies to cancer indications.
“We are looking forward to this partnership and working with CURE to continue uncovering the vast therapeutic potential of the cannabinoids found in various cannabis species,” said Technion researchers. “Accumulating evidence indicates that cannabinoids have anti-tumor effects, as several studies have demonstrated the use of cannabinoids in being able to regress different cancer types. This research research collaboration with CURE will help us with our goal of determining which cannabis strains might be used to tackle different cancer cells and what cannabinoid compounds within the plant are responsible for the ability to kill these cells.”
Looking Ahead
CURE Pharmaceutical’s (OTCQB: CURR) represents a compelling investment opportunity in the cannabinoid therapeutics space. With relatively few companies targeting cancer indications, the company is leveraging its significant experience in pharmaceuticals to develop potential cannabinoid therapeutics in conjunction with leading organizations like the Technion Research and Development Foundation – which has well-established expertise in the space.
For more information, visit the company’s website at www.curepharmaceutical.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]
Plus Products, through its wholly-owned subsidiary, Carberry, operates as a branded cannabis products manufacturer with operations in California.
Mojave Jane Brands Inc. is a Canadian-based cannabis sector brand and distribution company emerging as a true vertical integrator in California’s legal cannabis space serving recreational and wellness markets. The Company’s U.S. holdings are comprised of assets set up as a vertical stack including cultivation to scale, branding, packaging, manufacturing & processing, as well as, […]
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
